Heidelberg Pharma AG (0QW5) Price & Analysis

0 Followers

0QW5 Stock Chart & Stats

€2.39

€0.04(1.64%)

At close: Jan 06 4:00 PM EST

€2.39

€0.04(1.64%)

Day’s Range― - ―

52-Week Range€2.32 - €4.70

Previous CloseN/A

Volume39.00

Average Volume (3M)150.00

Market Cap

€119.30M

Enterprise Value€152.89

Total Cash (Recent Filing)€24.93M

Total Debt (Recent Filing)€45.98K

Price to Earnings (P/E)―

Beta0.50

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding46,784,317

10 Day Avg. Volume67

30 Day Avg. Volume150

Financial Highlights & Ratios

PEG Ratio-0.03

Price to Book (P/B)-12.31

Price to Sales (P/S)92.22

P/FCF Ratio-4.24

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Proprietary ATAC/ADC PlatformHeidelberg's Amanitin-based ATAC payload and ADC platform represent a durable technical differentiator. Proprietary toxic payload chemistry can drive long-term licensing, collaboration revenues and strategic partnerships, giving persistent commercial optionality beyond single programs.

Recent Revenue RecoveryA sharp TTM revenue rebound of +131.3% indicates meaningful pickup in partner funding or milestone income. Sustained top-line growth from collaborations can extend runway, validate external demand for the platform, and reduce near-term reliance on dilutive financing.

Low Leverage And Asset BaseMinimal reported debt combined with sizable assets (46.9M TTM) provides structural financial flexibility. Low leverage lowers fixed financing costs and preserves options to finance R&D via partner deals, debt or structured arrangements rather than immediately dilutive equity.

Bears Say

Negative Shareholders' EquityNegative shareholders' equity (-14.2M TTM) reflects cumulative losses that have eroded capital. This structural weakness constrains borrowing capacity, raises covenant and counterparty concerns, and increases the likelihood of equity issuance or restructuring to restore solvency.

Persistent Cash BurnConsistent negative operating cash flow and FCF (around -25M TTM) signal ongoing cash burn. Over a multi-month horizon this necessitates repeat external funding or milestone monetization, heightening dilution risk and constraining the pace of internally funded R&D progress.

Ongoing Deep Net Losses And Weak MarginsSubstantial net losses (-33.1M TTM) and heavy negative margins show operations are not yet self-sustaining. Even with gross profit positive, operating expenses outstrip revenues; until milestones or commercial revenues scale, execution and profitability risk remain elevated.

0QW5 FAQ

What was Heidelberg Pharma AG’s price range in the past 12 months?

Heidelberg Pharma AG lowest share price was €2.32 and its highest was €4.70 in the past 12 months.

What is Heidelberg Pharma AG’s market cap?

Heidelberg Pharma AG’s market cap is €119.30M.

When is Heidelberg Pharma AG’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Heidelberg Pharma AG’s earnings last quarter?

Currently, no data Available

Is Heidelberg Pharma AG overvalued?

According to Wall Street analysts Heidelberg Pharma AG’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Heidelberg Pharma AG pay dividends?

Heidelberg Pharma AG does not currently pay dividends.

What is Heidelberg Pharma AG’s EPS estimate?

Heidelberg Pharma AG’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Heidelberg Pharma AG have?

Heidelberg Pharma AG has 46,784,317 shares outstanding.

What happened to Heidelberg Pharma AG’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Heidelberg Pharma AG?

Currently, no hedge funds are holding shares in GB:0QW5

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Heidelberg Pharma AG Stock Smart Score

Underperform

Technicals

Fundamentals

Return on Equity

-5460.56%

Trailing 12-Months

Asset Growth

-24.91%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Heidelberg Pharma AG

Heidelberg Pharma AG is a biopharmaceutical firm dedicated to oncology, with a specific emphasis on its innovative antibody-targeted amanitin conjugates (ATAC) technology. The company conducts its activities across Germany, various other European countries, the United States, and globally. Its primary drug candidate, HDP-101, is presently in Phase I/IIa clinical trials for individuals suffering from relapsed or refractory multiple myeloma. The pipeline also features several other ATAC compounds: HDP-102 is being developed for non-Hodgkin lymphoma; HDP-103 targets metastatic castration-resistant prostate cancer; HDP-104 is aimed at various tumor types; and HDP-XX addresses both solid and hematological tumors. Further development programs include MGTA-ATACs, designed for hematopoietic stem cells (HSCs) and conditioning treatments for blood cancers and genetic conditions, alongside TAK-ATACs for broader oncology use. Heidelberg Pharma's offerings extend to diagnostic and therapeutic antibodies. TLX250-CDx, a diagnostic antibody for imaging purposes, is in Phase III for renal cancer, Phase I for urothelial carcinoma (bladder cancer), and Phase II for triple-negative breast cancer. Additionally, TLX250 (girentuximab), a therapeutic antibody, is undergoing Phase II evaluation for patients with advanced clear cell renal cell carcinoma. The company's diverse portfolio is complemented by RHB-107, an oral serine protease inhibitor in Phase II/III studies for both COVID-19 and advanced cholangiocarcinoma, as well as LH011 for pancreatic cancer. A significant licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. grants the latter development and commercialization rights for HDP-101 and HDP-103 throughout Asia. Established in Ladenburg, Germany, in 1997, the company was formerly known as Wilex AG before rebranding to Heidelberg Pharma AG in October 2017.